Open Access

[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition in vivo

  • Authors:
    • Xiaoqing Jia
    • Jingyi Cheng
    • Zhenzhou Shen
    • Zhimin Shao
    • Guangyu Liu
  • View Affiliations

  • Published online on: October 9, 2024     https://doi.org/10.3892/mmr.2024.13357
  • Article Number: 233
  • Copyright : © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Following the publication of the above article, the authors drew to the Editor’s attention that they had inadvertently used the same immunohistochemical image to show the experiments depicting the zoledronic acid‑treated MCF‑7/HIF‑1α xenograft (the ‘ZOL/MCF‑7/hif’ panel) and the fulvestrant‑treated MCF‑7/vector xenograft (the ‘FUL/MCF‑7/cdh’ panel) in Fig. 3A on p. 5474. Subsequently, upon performing an independent review of the data in this paper, the Editorial Office pointed out to the authors that the same colony‑formation assay image had been included in Fig. 1C to show the ‘MCF‑7/cdh‑ZOL’ and ‘MCF‑7/cdh‑FUL’ experiments. The authors re‑examined their original data, and realized that inadvertent errors were made during the compilation of this pair of figures. The corrected versions of Figs. 1 and 3 are shown on the next two pages, now featuring the correct data for the ‘MCF‑7/cdh‑ZOL’ experiment in Fig. 1C and the ‘ZOL/MCF‑7/hif’ experiment in Fig. 3A. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of Molecular Medicine Reports for granting them the opportunity to publish this. Furthermore, they regret that these errors were introduced into the paper, even though they did not substantially alter any of the major conclusions reported in the paper, and apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 17: 5470‑5476, 2018; DOI: 10.3892/mmr.2018.8514]

Related Articles

Journal Cover

December-2024
Volume 30 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jia X, Cheng J, Shen Z, Shao Z and Liu G: [Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <em>in vivo</em>. Mol Med Rep 30: 233, 2024.
APA
Jia, X., Cheng, J., Shen, Z., Shao, Z., & Liu, G. (2024). [Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <em>in vivo</em>. Molecular Medicine Reports, 30, 233. https://doi.org/10.3892/mmr.2024.13357
MLA
Jia, X., Cheng, J., Shen, Z., Shao, Z., Liu, G."[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <em>in vivo</em>". Molecular Medicine Reports 30.6 (2024): 233.
Chicago
Jia, X., Cheng, J., Shen, Z., Shao, Z., Liu, G."[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition <em>in vivo</em>". Molecular Medicine Reports 30, no. 6 (2024): 233. https://doi.org/10.3892/mmr.2024.13357